title: Management of type IIb dyslipidemia.
abstract: Although the Japan Atherosclerosis Society guideline for the diagnosis and prevention of atherosclerosis cardiovascular diseases for the Japanese population provides targets for low-density lipoprotein (LDL) cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol to prevent cardiovascular disease in patients with dyslipidemia, there is no guideline specifically targeting the treatment of type IIb dyslipidemia, which is one of the most common types of dyslipidemia, along with type IIa and type IV dyslipidemia. Type IIb dyslipidemia is important because it sometimes accompanies atherogenic lipid profiles, such as small, dense LDL, remnants, low HDL cholesterolemia. It is also associated with type 2 diabetes mellitus, metabolic syndrome, and chronic kidney disease (CKD), and most patients with familial combined hyperlipidemia (FCHL) show this phenotype; therefore, it is assumed that patients with type IIb dyslipidemia have a high risk for cardiovascular disease. Thus, the management of type IIb dyslipidemia is very important for the prevention of cardiovascular disease, so we have attempted to provide a guideline for the management of type IIb dyslipidemia.
authors.affiliation: Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. harai@kuhp.kyoto-u.ac.jp
authors.forename: Hidenori
authors.initials: H
authors.lastname: Arai
authors.forename: Shun
authors.initials: S
authors.lastname: Ishibashi
authors.forename: Hideaki
authors.initials: H
authors.lastname: Bujo
authors.forename: Toshio
authors.initials: T
authors.lastname: Hayashi
authors.forename: Shinji
authors.initials: S
authors.lastname: Yokoyama
authors.forename: Shinichi
authors.initials: S
authors.lastname: Oikawa
authors.forename: Junji
authors.initials: J
authors.lastname: Kobayashi
authors.forename: Kohji
authors.initials: K
authors.lastname: Shirai
authors.forename: Takao
authors.initials: T
authors.lastname: Ota
authors.forename: Shizuya
authors.initials: S
authors.lastname: Yamashita
authors.forename: Takanari
authors.initials: T
authors.lastname: Gotoda
authors.forename: Mariko
authors.initials: M
authors.lastname: Harada-Shiba
authors.forename: Hirohito
authors.initials: H
authors.lastname: Sone
authors.forename: Masaaki
authors.initials: M
authors.lastname: Eto
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Suzuki
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Yamada
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000517:prevention & control*; D019468:Disease Management; D050171:Dyslipidemias / Q000150:complications / Q000517:prevention & control*; D006801:Humans; D024821:Metabolic Syndrome / Q000209:etiology / Q000517:prevention & control*